Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial

• Principais autores: Todd Hulgan (Autor), M. Sean Boger (Autor), Diana H. Liao (Autor), Grace A. McComsey (Autor), Christine A. Wanke (Autor), Alexandra Mangili (Autor), Sharon L. Walmsley (Autor), Heather McCreath (Autor), Ginger L. Milne (Autor), Stephanie C. Sanchez (Autor), Judith S. Currier (Autor), Jordan E. Lake (Autor)
• Formato: Livro
• Publicado em: Hindawi Limited, 2014-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects. We assessed urinary F2-isoprostanes (F2-IsoP...